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Abstract
Introduction: Lung cancer is now considered the most common cause of death among cancer patients. Although
target biological regimens have emerged in recent years for non-small cell lung carcinoma, the survival and quality
of life of patients with this condition still remain low. The five-year survival rate for all stages of lung cancer is 17%
or less.
Case presentation: We describe the case of a 53-year-old Caucasian woman who was diagnosed with advanced
stage IIIa (T2aN2M0) non-small cell lung carcinoma (adenocarcinoma) and underwent a complete left upper
lobectomy three years ago. After two and a half years of follow-up, she suddenly presented with facial edema and
venous distension and was immediately treated for superior vena cava syndrome. Because of a diagnostic check, a
major clot was detected in the right subclavian vein. Our patient was informed about treatment options, and she
was taken to the catheterization laboratory for percutaneous stenting of the superior vena cava to restore superior
vena cava patency.
Conclusion: Lung cancer has a vast number of complications. Superior vena cava syndrome and thrombosis
should be considered upon the presentation of a patient with obstructive symptoms. In this case report, even
though we expected the clot to be on the side of the former lesion, it was present on the opposite side.
Treatment should also start immediately in these patients with clinical suspicion of thrombosis to avoid further
complications, even in cases with a differential diagnosis problem. Finally, although patients with non-small cell
lung carcinoma have a high incidence of thromboembolic events, anticoagulant treatment is given only as
maintenance therapy after a first event occurs.
Introduction
Lung cancer is one of the leading causes of death in the
European Union, with an incidence of approximately
180,000 cases per year [1]. Superior vena cava syndrome
(SVCS) is a well-known manifestation of benign and
malignant tumors of the upper mediastinum, that causes
obstruction of blood flow through the superior vena
cava (SVC) [2] in approximately 1.7% to 4% of patients
with lung cancer [2,3]. Most of the cases are caused by
compression of the SVC by tumors; pure intravascular
thrombosis is extremely uncommon and only 0.04% of
hospitalized adults have been diagnosed with cancer-
related SVC thrombosis [3,4]. Percutaneous treatment
via stenting is an accepted strategy as a palliative
approach for patients with SVCS if it is impossible to
treat the underlying disease, most commonly a meta-
static tumor, and when the patient is highly sympto-
matic [5]. This report discusses a rare case of SVCS by
cancer-related thrombosis treated with endovascular
stenting, resulting in complete restoration of blood flow
and immediate relief of symptoms without any
complications.
Case presentation
A 53-year-old Caucasian woman consulted our depart-
ment complaining of progressively worsening facial
swelling and a feeling of “t e n s i o ni nt h eh e a d , ” which
she had first experienced eight days previously and had
gradually worsened. Our patient had a history of locally
advanced lung cancer (stage T2aN2M0-IIIa). It was first
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attached to the mediastinum and was treated with left
upper lobe complete resection. The pathologic examina-
tion revealed poorly differentiated adenocarcinoma. Our
patient was subsequently treated with six cycles of tax-
ane and platinum chemotherapy and radiotherapy at the
primary site. It was decided to initiate a complete che-
motherapy regimen for locally advanced lymph node
disease N2. After two and a half years of follow-up, our
patient was diagnosed with progressive disease (left
supraclavicular nodes and sternum bone metastases),
and at the time of examination, she was not receiving
any treatment. Her physical examination revealed facial
edema and thoracic and upper limb venous distension
(Figure 1). The differential diagnosis included central
venous obstruction or thrombosis, including SVCS. A
chest radiograph showed no progression of the disease
in either hemithorax at the time of symptom presenta-
tion (Figure 2). Her blood examination results were as
follows: white blood cell count 5770/mm
3, hemoglobin
8.4 g/dL, platelets 253 × 10
4/mm
3, glucose 92 mg/dL,
creatine 1.23 mg/dL, aspartate aminotransferase 20IU/L,
alanine aminotransferase, 10IU/L, alkaline phosphatase
107IU/L, lactate dehydrogenase 382IU/L, albumin 2.8 g/
dL, total bilirubin 0.6 mg/dL, sodium (Na
+) 141.4 mEq/
L, potassium (K
+) 4.3 mEq/L, calcium (Ca
2+) 8.9 mg/dL,
uric acid 4.1 mg/dL, international normalized ratio
(INR) 0.94, and D-dimers 4300 μg/mL.
Our patient was clinically diagnosed with SVCS, and
contrast-enhanced computed tomography (CT) was per-
formed to confirm the diagnosis. Enhanced neck CT
demonstrated a major thrombus-like lesion inside her
right jugular vein (Figure 3). The standard therapeutic
treatment modality for SVCS is radiotherapy, but
because of the CT angiography findings, our patient was
sent to the catheterization laboratory for percutaneous
stenting. The stenosis in the right jugular vein was
transversed with a 0.35 inch guidewire (Bioart, Tokyo,
Japan) and an 8Fr guiding catheter (Boston Scientific,
Natick, MA, USA). The obstruction was dilated using a
3.0 mm×80 mm balloon, and a stent (Dynamic Balloon-
Expandable Stent; Abbott Laboratories, Abbott Park, IL,
USA) of equal size (3.0 mm×56 mm) was implanted in
her right subclavical vein. After the stent placement
(Figure 4), our patient showed immediate relief of her
symptoms, and she was discharged home the day after
the procedure on anticoagulant therapy (warfarin, to
maintain prothrombin time INR between 2.0 and 2.5).
Five months after the stenting procedure our patient is
still asymptomatic with no signs of SVCS on physical
Figure 1 Image showing facial edema and venous distension.
Figure 2 Chest radiograph taken on the day of the thrombus
diagnosis.
Figure 3 Contrast-enhanced CT of the chest demonstrating
thrombosis at the level of the right subclavicular vein.
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ment with an optimal therapeutic INR level.
Discussion
Malignancy in non-small cell lung carcinoma (NSCLC)
is the most common cause of SVCS, as a result of either
compression of the SVC by an adjacent tumor or com-
pression by mediastinal lymph nodes. However, because
the velocity of blood flow in the SVC is too fast to per-
mit blood thrombosis, the development of SVC throm-
bosis alone is extremely rare [4-6]. In patients with
neoplastic disease, a syndrome can occur with recurrent
thrombosis in unusual areas (including SVC), known as
Trousseau’s syndrome. Reported varieties of underlying
malignancies in patients with Trousseau’ss y n d r o m e
include pancreatic cancers (32.5%), lung cancers (23.6%),
gastrointestinal cancers (17.1%) and other cancers
(26.8%) [7]. The main pathophysiologic mechanisms of
Trousseau’s syndrome are malignancy-related hypercoa-
gulability and tumor cell injury of the vascular endothe-
lium, followed by platelet aggregation and activation and
consumption of anti-thrombin III and thrombomodulin.
Takeda et al. [6] reported the case of a patient with
SVC thrombosis in which the major etiologic pathway
was suggested to be metastasis of cancer cells to the
SVC vessel endothelium from lymphatic drainage
through the thoracic duct leading to the left innominate
vein via the left jugulosubclavicular angle. The attach-
ment of metastatic cells to the vessel endothelium was
considered as the trigger to thrombus formation, consid-
ering the existence of malignant cells in the intra-SVC
thrombus.
SVCS is often diagnosed clinically on the basis of
symptoms of venous congestion, including facial and
neck swelling, dyspnea and headache. Venous Doppler
ultrasonography, contrast-enhanced CT and magnetic
resonance imaging are contributory diagnostic modal-
ities when the diagnosis is unclear [8]. In malignancy-
associated SVCS, treatment is generally directed at the
malignant disease process. Treatment modalities avail-
able for SVCS include local radiation (radiation therapy
to the malignant process to provide decompression),
chemotherapy, steroids (useful only for patients with
SVC obstruction as a result of lymphoma) and occasion-
ally diuretic therapy [2].
Endovascular options for the treatment of patients
with SVCS in the setting of lung cancer include throm-
bolysis, angioplasty and stent placement. The use of
angioplasty and stenting has developed over the past 15
years. Initially, SVC stents were used in patients who
failed to respond to traditional therapy or whose symp-
toms recurred after traditional therapy. In this patient
population, SVC stents have had dramatic technical and
clinical results; relief of SVC obstruction has been
demonstrated in more than 90% of these patients and
obtained with a delay of 24 to 72 hours [5,9]. The
researchers in all of these studies investigated the effi-
c a c yo fs t e n t i n gi nS V Co b s t r u c t i o ni nt h es e t t i n go f
both small cell lung cancer and NSCLC, but none have
reported results individually by histological type. Given
the excellent results in this patient population, more
recently a few authors have suggested that stenting
should be used as initial therapy in all patients with
malignant SVCS and not only after treatment failure or
symptom recurrence after classical treatment. The find-
ings from a large number of case series demonstrate
excellent clinical results and low complication rates [10].
With the high success rate of stenting (decreased time
to SVC obstruction relapse, increased overall survival
and nearly complete and immediate relief of symptoms),
endovascular treatment has become the primary safe,
consistent, and cost-effective treatment choice for
patients with SVCS [5,10]. For stent placement, the
patient’s condition must be stable enough for the patient
to undergo a one to three hour procedure, and coagulo-
pathies should be corrected.
Complications of stent placement have been reported
in 3% to 7% of patients with SVCS [11]. The most com-
mon complications of this therapy are stent thrombosis
and stent migration or misplacement [11]. The risk of
stent thrombosis is significantly reduced when long-
term anticoagulation with warfarin is used after endo-
vascular stenting [11]. The role of anticoagulation has
been debated in the literature. Anticoagulation therapy
is often prescribed for patients with SVC obstruction or
after stenting, although its effectiveness has never been
Figure 4 Chest radiograph showing the stent placed in the
right subclavicular vein and superior vena cava through
thrombosis.
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ticlopidine) and length of preventive treatment remain
controversial [5,10,11]. Some authors recommend that
all patients with new stents undergo short-term (three
to six months) anticoagulation while endothelialization
takes place, because significant pulmonary emboli may
result. Others recommend long-term anticoagulation in
this setting, and others sugge s tt h a ta n t i c o a g u l a t i o n
must be used with caution in patients with malignancies
[12]. Other complications reported in the literature
include infection, pulmonary embolus, hematoma at the
insertion site, bleeding, thoracic pain during balloon
inflation [5,9], perforation or rupture of the vein, cardiac
tamponade, acute cardiogenic pulmonary edema and
transient hemidiaphragm elevation [5,9,13,14].
Cancer patients undergoing surgery or bedridden with
acute medical illness should receive routine thrombopro-
phylaxis (that is, what is customarily used on the basis of
the type of surgery or for patients with acute medical ill-
ness). In cancer patients with indwelling central venous
catheters, the American College of Chest Physicians
(ACCP) advises against using prophylactic doses of low-
molecular-weight heparin or mini-dose warfarin (that is,
1 mg/day) for the prevention of catheter-related throm-
bosis. The routine use of thromboprophylaxis for primary
prevention of venous thromboembolic event (VTE) is not
recommended for cancer patients receiving chemother-
apy or hormonal therapy. The routine use of primary
thromboprophylaxis for improvement of survival in can-
cer patients is also not recommended [15].
In our report, we present the case of a patient with
upper left lobe lung disease and cancer-related thrombo-
sis of the right subclavicular vein that led to SVCS after
surgical resection. We report this case because we
would usually expect the thrombus to form on the left
hemithorax because of the regional effects of the cancer
cells. Also, at the time of symptom presentation, our
patient did not have lung disease. This case report illus-
trates the effectiveness of vascular stenting in the man-
agement of SVCS in a lung cancer patient with
subclavicular thrombosis. Because SVC obstruction is a
highly stressful complication for patients with lung can-
cer, we used endovascular stenting as the main thera-
peutic intervention for an effective and fast-acting
procedure. Our patient was in addition receiving antic-
oagulation therapy for the prevention of further throm-
bosis and recurrence. We believe that, given the efficacy
of endovascular stenting, future patients will undergo
vascular stenting as the first-line treatment despite the
elevated cost of this relatively new technique.
Conclusion
Lung cancer is a well-known predisposing factor for
thrombosis. Central venous thrombosis should be
included in the differential diagnosis of a patient with
symptoms that could be attributed to venous obstruc-
tion. The results achieved with endovascular stents in
the treatment of SVCS of malignant causes are excel-
lent, and percutaneous endovascular stent insertion is
an effective treatment for palliation of SVCS because it
provides immediate and sustained symptomatic relief.
The high response rates, quickness of effect and safety
make this palliative treatment a useful tool and a can-
didate for being the potential standard in the manage-
ment of SVC obstruction. It has not yet been
established whether cancer patients without locally
recurrent disease should receive anticoagulant therapy.
The risk of deep venous thrombosis is low in cancer
patients without additional risk factors. This fact is in
accordance with the ACCP guidelines, which do not
recommend routine prophylaxis for VTE prevention in
cancer patients in itself [15]. The risk steadily increases
with the number of risk factors. Thus, risk assessment
tools seem to be sensible to stratify prophylactic regi-
mens in these patients. Risk assessment is mandatory
to identify patients at high risk with respect to the
application of prophylactic therapeutic regimens, which
have to be carefully investigated in randomized clinical
studies.
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